Understanding Trop-2 in advanced prostate cancer to find better treatments
Official title: Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
Funded at University of Wisconsin-Madison · NIH-11120973 · Data updated 2026-11-12
This project looks for new ways to treat advanced prostate cancer by understanding a specific protein called Trop-2.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $651,191 |
| NIH project number | 5R01CA276269-03 |
| Project ID | NIH-11120973 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is most relevant to men living with metastatic castrate-resistant prostate cancer (mCRPC) who are seeking new treatment options.
✕Less likely to help
Patients whose prostate cancer is still responding well to existing treatments or who do not have advanced, resistant disease may not directly benefit from this specific research.
What this research studies
For men with advanced prostate cancer that has become resistant to standard treatments, finding new options is crucial. This project explores the role of a protein called Trop-2 in these aggressive cancers. By learning how Trop-2 works and is expressed, we hope to uncover new weaknesses in cancer cells. This understanding could lead to more effective, targeted therapies for patients who currently have limited choices.
Why it matters
Potential benefit: If successful, this work could lead to the development of new, more effective treatments for men with advanced prostate cancer that no longer responds to current therapies.
How similar studies have gone: While current treatments for advanced prostate cancer have improved, there is a critical need for new agents to overcome resistance, suggesting this approach explores novel therapeutic targets.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Lang, Joshua — University of Wisconsin-Madison
- Study coordinator: Lang, Joshua
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.